+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Hormone Replacement Therapy Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797861
The global hormone replacement therapy market value was USD 30.04 billion in 2022, driven by the increasing prevalence of hormonal imbalances across the globe. The market size is anticipated to grow at a CAGR of 5.9% during the forecast period of 2023-2031to achieve a value of USD 50.9 billion by 2031.

Hormone Replacement Therapy: Introduction

Hormone replacement therapy (HRT) is a medical treatment used to replace or supplement the hormones that the body no longer produces in sufficient amounts. HRT is commonly used to alleviate symptoms associated with menopause in women, such as hot flashes, night sweats, mood changes, and bone loss. In men, testosterone replacement therapy is used to treat conditions related to low testosterone levels, including decreased libido, fatigue, and loss of muscle mass. Additionally, hormone replacement therapy can also be employed to manage various endocrine disorders, such as hypothyroidism and adrenal insufficiency.

Hormone Replacement Therapy Market Scenario

The global hormone replacement therapy market has witnessed significant growth in recent years, driven by factors such as the increasing prevalence of hormonal imbalances, an aging population, and growing awareness of the benefits of HRT. The market has also been fuelled by advancements in drug delivery systems, the development of novel hormonal treatments, and a supportive regulatory environment.

North America: The largest market for hormone replacement therapy, driven by factors such as the high prevalence of hormonal imbalances, advanced healthcare infrastructure, and a strong focus on research and development.

Europe: The second-largest market, with increasing demand for hormone replacement therapy due to a growing awareness of its therapeutic benefits and a supportive regulatory framework.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly aging population, increasing prevalence of hormonal imbalances, and growing investments in healthcare infrastructure.

Market Segmentation

Market Breakup by Product

  • Estrogen and Progesterone Replacement Therapy
  • Human Growth Hormone Replacement Therapy
  • Thyroid Replacement Therapy
  • Testosterone Replacement Therapy
  • Others

Market by Route of Administration

  • Oral
  • Parenteral
  • Transdermal
  • Other

Market Breakup by Type of Disease

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Others

Market Breakup by End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Hormone Replacement Therapy Market

Some key trends of the market are as follows:
  • Growing demand for bioidentical hormones: There is an increasing demand for bioidentical hormones, which are chemically identical to the hormones produced by the body, as they are believed to have fewer side effects compared to synthetic hormones
  • Advancements in drug delivery systems: The development of innovative drug delivery systems, such as transdermal patches and gels, has improved the safety, efficacy, and patient adherence to HRT, fuelling market growth
  • Expanding therapeutic applications: The ongoing research and development efforts have led to the discovery of new therapeutic applications for hormone replacement therapy, such as the treatment of certain cancers and the management of osteoporosis

Hormone Replacement Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Novo Nordisk A/S
  • Abbott Laboratories Inc
  • Pfizer Inc
  • Allergan
  • Bayer AG
  • Merck & Co., Inc
  • Viatris Inc
  • Eli Lilly and Company
  • Koninklijke Philips N.V
  • F. Hoffmann-La Roche Ltd. (Genentech)
  • Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)
  • ASCEND Therapeutics US, LLC. (Besins Healthcare)
  • AbbVie Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Hormone Replacement Therapy Overview
3.1 Global Hormone Replacement Therapy Market Historical Value (2016-2022)
3.2 Global Hormone Replacement Therapy Market Forecast Value (2023-2031)
4 Global Hormone Replacement Therapy Market Landscape
4.1 Global Hormone Replacement Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Hormone Replacement Therapy Product Landscape
4.2.1 Analysis by Patent Type
4.2.2 Analysis by End user
4.2.3 Analysis by Distribution Channel
5 Global Hormone Replacement Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Hormone Replacement Therapy Market Segmentation
6.1 Global Hormone Replacement Therapy Market by Product
6.1.1 Market Overview
6.1.2 Estrogen & Progesterone Replacement Therapy
6.1.3 Human Growth Hormone Replacement Therapy
6.1.4 Thyroid Replacement Therapy
6.1.5 Testosterone Replacement Therapy
6.1.6 Others
6.2 Global Hormone Replacement Therapy Market by Route of Administration
6.2.1 Market Overview
6.2.2 Oral
6.2.3 Parenteral
6.2.4 Transdermal
6.2.5 Other
6.3 Global Hormone Replacement Therapy Market by Type of Disease
6.3.1 Market Overview
6.3.2 Menopause
6.3.3 Hypothyroidism
6.3.4 Male Hypogonadism
6.3.5 Growth Hormone Deficiency
6.3.6 Others
6.4 Global Hormone Replacement Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Specialty Clinics
6.4.5 Others
6.5 Global Hormone Replacement Therapy Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.4 Online Pharmacy
6.6 Global Hormone Replacement Therapy Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Hormone Replacement Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Hormone Replacement Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Hormone Replacement Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Hormone Replacement Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Hormone Replacement Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 Novo Nordisk A/S
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Abbott Laboratories Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Pfizer Inc
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Allergan
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Bayer AG
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Merck & Co., Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Viatris Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Eli Lilly and Company
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Koninklijke Philips N.V.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 F. Hoffmann-La Roche Ltd. (Genentech)
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 ASCEND Therapeutics US, LLC. (Besins Healthcare)
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 AbbVie Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Hormone Replacement Therapy Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Novo Nordisk A/S
  • Abbott Laboratories Inc.
  • Pfizer Inc
  • Allergan
  • Bayer AG
  • Merck & Co. Inc.
  • Viatris Inc.
  • Eli Lilly and Company
  • Koninklijke Philips N.V.
  • F. Hoffmann-La Roche Ltd. (Genentech)
  • Hisamitsu Pharmaceutical Co. Inc. (Noven Pharmaceuticals, Inc.)
  • Ascend Therapeutics Us, LLC. (Besins Healthcare)
  • Abbvie Inc.



Table Information